

Michal Zikan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/127734/publications.pdf>

Version: 2024-02-01

81
papers

4,088
citations

134610

34
h-index

134545

62
g-index

84
all docs

84
docs citations

84
times ranked

6682
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative staging of ovarian cancer: comparison between ultrasound, <sc>CT</sc> and whole-body diffusion-weighted <sc>MRI</sc> (<sc>ISAAC</sc> study). <i>Ultrasound in Obstetrics and Gynecology</i> , 2022, 59, 248-262.	0.9	11
2	Toxoplasmosis impact on prematurity and low birth weight. <i>PLoS ONE</i> , 2022, 17, e0262593.	1.1	10
3	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. <i>Nature Communications</i> , 2022, 13, 449.	5.8	21
4	Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. <i>Genome Biology</i> , 2022, 23, 52.	3.8	8
5	Diagnostic Reliability, Accuracy and Safety of Ultrasound-guided Biopsy and Ascites Puncture in Primarily Inoperable Ovarian Tumours. <i>Anticancer Research</i> , 2020, 40, 3527-3534.	0.5	7
6	Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer. <i>Cancers</i> , 2020, 12, 956.	1.7	19
7	Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22½ cases. <i>Oncology Letters</i> , 2019, 17, 2207-2214.	0.8	12
8	Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. <i>Lancet Oncology</i> , The, 2019, 20, 1171-1182.	5.1	108
9	The association among cervical, anal, and oral HPV infections in high-risk and low-risk women. <i>European Journal of Obstetrics and Gynecology and Reproductive Biology: X</i> , 2019, 4, 100061.	0.6	9
10	A Novel Approach to Preoperative Risk Stratification in Endometrial Cancer: The Added Value of Immunohistochemical Markers. <i>Frontiers in Oncology</i> , 2019, 9, 265.	1.3	19
11	Ultrasound characteristics of a symptomatic and asymptomatic lymphocele after pelvic and/or paraaortic lymphadenectomy. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2019, 58, 266-272.	0.5	7
12	A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. <i>Gynecologic Oncology</i> , 2018, 149, 140-145.	0.6	9
13	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 292-309.	12.5	129
14	Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. <i>Modern Pathology</i> , 2018, 31, 816-828.	2.9	46
15	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. <i>International Journal of Cancer</i> , 2018, 142, 1230-1243.	2.3	59
16	Ultrasound in preoperative assessment of pelvic and abdominal spread in patients with ovarian cancer: a prospective study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 263-274.	0.9	33
17	Pelvic floor reconstruction by modified rectus abdominis myoperitoneal (MRAM) flap after pelvic exenterations. <i>Gynecologic Oncology</i> , 2017, 144, 558-563.	0.6	20
18	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas – an ENITEC Group Initiative. <i>Clinical Cancer Research</i> , 2017, 23, 1274-1285.	3.2	30

#	ARTICLE	IF	CITATIONS
19	The association of enchondromatosis with malignant transformed chondrosarcoma and ovarian juvenile granulosa cell tumor (Ollier disease). <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2017, 56, 253-257.	0.5	21
20	Sensitivity of Follow-Up Methods in Patients After Fertility-Sparing Surgery for Cervical Cancers. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 147-153.	1.2	8
21	Methylation patterns in serum DNA for early identification of disseminated breast cancer. <i>Genome Medicine</i> , 2017, 9, 115.	3.6	49
22	The Diagnostic Accuracy of Ultrasound in Assessment of Myometrial Invasion in Endometrial Cancer: Subjective Assessment versus Objective Techniques. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	25
23	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017, 9, 116.	3.6	122
24	Prospective Evaluation of Ultrasound Accuracy in the Detection of Pelvic Carcinomatosis in Patients with Ovarian Cancer. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 2196-2202.	0.7	9
25	Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer. <i>Gynecologic Oncology</i> , 2016, 143, 83-86.	0.6	35
26	Results of less radical fertility-sparing procedures with omitted parametrectomy for cervical cancer: 5years of experience. <i>Gynecologic Oncology</i> , 2016, 142, 401-404.	0.6	24
27	Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1311-1321.	1.1	25
28	Atypical Polypoid Adenomyoma of the Uterus. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1148-1155.	2.1	42
29	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
30	Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. <i>Modern Pathology</i> , 2015, 28, 1001-1010.	2.9	60
31	A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer. <i>Gynecologic Oncology</i> , 2015, 137, 291-298.	0.6	98
32	Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 415-422.	1.4	34
33	Ovarian metastasis of clear cell renal cell carcinoma: A case report. <i>Canadian Urological Association Journal</i> , 2014, 8, 188.	0.3	6
34	Lymphocele: prevalence and management in gynecological malignancies. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 307-317.	1.1	41
35	Pelvic Lymphadenectomy Improves Survival in Patients With Cervical Cancer With Low-Volume Disease in the Sentinel Node: A Retrospective Multicenter Cohort Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 303-311.	1.2	30
36	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. <i>Genome Medicine</i> , 2014, 6, 47.	3.6	53

#	ARTICLE	IF	CITATIONS
37	Factors affecting sonographic preoperative local staging of endometrial cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014, 43, 575-585.	0.9	42
38	DNA methylation markers for early detection of women's cancer: promise and challenges. <i>Epigenomics</i> , 2014, 6, 311-327.	1.0	76
39	A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial. <i>BMC Cancer</i> , 2014, 14, 635.	1.1	12
40	Early-stage cervical cancer: Tumor delineation by magnetic resonance imaging and ultrasound – A European multicenter trial. <i>Gynecologic Oncology</i> , 2013, 128, 449-453.	0.6	115
41	Transrectal ultrasound and magnetic resonance imaging in the evaluation of tumor size following neoadjuvant chemotherapy for locally advanced cervical cancer. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 705-712.	0.9	23
42	Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. <i>PLoS Medicine</i> , 2013, 10, e1001551.	3.9	135
43	The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer. <i>PLoS Genetics</i> , 2012, 8, e1002517.	1.5	111
44	Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors. <i>Oncologist</i> , 2012, 17, 1515-1533.	1.9	161
45	Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. <i>Gynecologic Oncology</i> , 2012, 127, 462-466.	0.6	108
46	Ultrasonographic appearance of metastatic non-gynecological pelvic tumors. <i>Ultrasound in Obstetrics and Gynecology</i> , 2012, 39, 215-225.	0.9	15
47	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. <i>British Journal of Cancer</i> , 2012, 106, 2016-2024.	2.9	27
48	Outcomes of pregnant patients with Pap smears classified as atypical glandular cells. <i>Cytopathology</i> , 2012, 23, 383-388.	0.4	7
49	Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2012, 124, 496-501.	0.6	174
50	Sentinel lymph node status in patients with locally advanced cervical cancers and impact of neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2012, 125, 303-306.	0.6	23
51	High-risk human papillomavirus DNA in paraaortic lymph nodes in advanced stages of cervical carcinoma. <i>Journal of Clinical Virology</i> , 2011, 50, 46-49.	1.6	5
52	Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 559-563.	1.3	38
53	Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 652-655.	1.2	4
54	Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1197-1207.	1.1	96

#	ARTICLE	IF	CITATIONS
55	Local Control After Tailored Surgical Treatment of Early Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 690-698.	1.2	19
56	Human Papillomavirus DNA Presence in Pelvic Lymph Nodes in Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 126-132.	1.2	5
57	Factors Affecting Spontaneous Voiding Recovery After Radical Hysterectomy. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 685-690.	1.2	23
58	Ultrasound-guided tru-cut biopsy of abdominal and pelvic tumors in gynecology. <i>Ultrasound in Obstetrics and Gynecology</i> , 2010, 36, 767-772.	0.9	53
59	Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 337-347.	1.1	33
60	Late morbidity following nerve-sparing radical hysterectomy. <i>Gynecologic Oncology</i> , 2010, 116, 506-511.	0.6	54
61	Population-based study of BRCA1/2 mutations: Family history based criteria identify minority of mutation carriers. <i>Neoplasia</i> , 2010, 57, 280-285.	0.7	7
62	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. <i>Cancer Research</i> , 2010, 70, 9742-9754.	0.4	169
63	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2010, 19, 2886-2897.	1.4	60
64	Hormonal contraception and risk of cancer. <i>Human Reproduction Update</i> , 2010, 16, 631-650.	5.2	199
65	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009, 18, 4442-4456.	1.4	99
66	Sentinel node (SLN) biopsy in the management of locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2009, 115, 46-50.	0.6	32
67	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. <i>International Journal of Cancer</i> , 2009, 125, 2214-2218.	2.3	59
68	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). <i>British Journal of Cancer</i> , 2009, 101, 2048-2054.	2.9	15
69	Abdominal Radical Trachelectomy in Fertility-Sparing Treatment of Early-Stage Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1407-1411.	1.2	71
70	High-Risk Human Papillomavirus DNA in the Primary Tumor, Sentinel, and Nonsentinel Pelvic Lymph Nodes in Patients With Early-Stage Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 703-707.	1.2	14
71	Ultrasound-guided tru-cut biopsy in the management of advanced abdomino-pelvic tumors. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 833-837.	1.2	41
72	Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 766-772.	1.2	119

#	ARTICLE	IF	CITATIONS
73	Novel complex genomic rearrangement of the BRCA1 gene. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 637, 205-208.	0.4	5
74	<i>AURKA</i>F31I Polymorphism and Breast Cancer Risk in<i>BRCA1</i>and<i>BRCA2</i>Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1416-1421.	1.1	30
75	RAD51 135Gâ†C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	2.6	217
76	Localization of the Sentinel Node of the Upper Outer Breast Quadrant in the Axillary Quadrants. Annals of Surgical Oncology, 2007, 14, 633-637.	0.7	11
77	High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer. Journal of Genetics, 2007, 86, 169-171.	0.4	5
78	Novel somatic mutations in the BRCA1 gene in sporadic breast tumors. Human Mutation, 2005, 25, 319-319.	1.1	21
79	Mutational analysis of theBRCA1 gene in 30 Czech ovarian cancer patients. Journal of Genetics, 2005, 84, 63-67.	0.4	8
80	High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Research, 2005, 7, R728-36.	2.2	59
81	Mutations of the <i>BRCA1</i> Gene in Hereditary Breast and Ovarian Cancer in the Czech Republic. Medical Principles and Practice, 2003, 12, 23-29.	1.1	22